The 1977 Nobel Prize for Hypothalamic Hormones
| Category | Research |
|---|---|
| Also known as | Guillemin Schally Nobel, hypothalamic peptides Nobel |
| Last updated | 2026-04-14 |
| Reading time | 3 min read |
| Tags | historynobel-prizehypothalamusTRHGnRH |
Overview
The 1977 Nobel Prize in Physiology or Medicine was shared, with half to Rosalyn Yalow for radioimmunoassay and half jointly to Roger Guillemin and Andrew Schally "for their discoveries concerning the peptide hormone production of the brain." The citation recognized the isolation and chemical characterization of thyrotropin releasing hormone, gonadotropin releasing hormone, and related hypothalamic peptides.
These discoveries confirmed the hypothesis, championed earlier by Geoffrey Harris, that hypothalamic peptides regulate anterior pituitary function through a dedicated portal circulation. Before the Guillemin-Schally era, this was an inference supported by anatomy and physiology but lacking molecular proof. Their isolation of specific releasing hormones turned the hypothesis into established fact.
The competition between Guillemin's and Schally's laboratories was intense and sometimes acrimonious. Both groups processed enormous numbers of animal hypothalami — hundreds of thousands in each case — to produce milligram quantities of pure peptide. The TRH structure was independently confirmed by both laboratories within a few months of each other in 1969.
Key People
- Roger Guillemin (1924–2024): Co-recipient, based at the Salk Institute.
- Andrew Schally (b. 1926): Co-recipient, based at Tulane/VA New Orleans.
- Rosalyn Yalow: Co-recipient for the RIA half of the prize.
- Geoffrey Harris (1913–1971): Earlier neuroendocrinologist whose hypothesis the 1977 prize confirmed.
- Paul Brazeau and Wylie Vale: Younger collaborators who contributed to somatostatin and CRH respectively.
Timeline
- 1955: Harris publishes Neural Control of the Pituitary Gland.
- 1969: Guillemin and Schally independently report the TRH structure.
- 1971: Schally reports LHRH/GnRH.
- 1973: Guillemin reports somatostatin.
- 1977: Nobel Prize awarded.
- 1981: Vale reports CRH.
- 1982: Guillemin reports GHRH.
Background
The Guillemin-Schally rivalry is one of the most storied chapters in modern biomedical research. Nicholas Wade's book The Nobel Duel (1981) documented how intense the competition became and how it sometimes spilled over into personal conflict. At the same time, the two laboratories produced a remarkable body of work that could not have been replicated by a single group.
The prize highlighted an important principle in neuroendocrinology: that the brain, via the hypothalamus, uses specific peptide hormones — rather than vague "neurohumors" — to direct the pituitary and, through the pituitary, much of endocrine physiology. This molecular view reshaped the discipline and led to the many clinically important hypothalamic peptide analogs now in use.
Modern Relevance
The hypothalamic peptides and their analogs are now central to clinical medicine. GnRH agonists and antagonists are used for prostate cancer, endometriosis, fibroids, precocious puberty, and assisted reproduction. Somatostatin analogs treat acromegaly, neuroendocrine tumors, and variceal bleeding (as part of octreotide's indications). CRH is used diagnostically in petrosal sinus sampling for Cushing disease. TRH remains a research and diagnostic tool.
The 1977 Nobel also validated the large-scale natural-product approach to peptide discovery. Although molecular cloning would soon complement and often replace mass-action purification, the catalog of hypothalamic peptides established by Guillemin and Schally continues to define the landscape of modern reproductive and endocrine medicine. See also nobel-prize-radioimmunoassay.
Related Compounds
Related entries
- Andrew Schally— Andrew Schally is a Polish-American neuroendocrinologist who shared the 1977 Nobel Prize for isolating hypothalamic peptide hormones.
- Roger Guillemin— Roger Guillemin was a French-American neuroendocrinologist who isolated TRH, GnRH, and somatostatin, sharing the 1977 Nobel Prize.
- The Discovery of Somatostatin— Somatostatin, the hypothalamic peptide that inhibits growth hormone release, was identified in 1973 by Brazeau and Guillemin.